PhD (Economics)

Steve Morgan is a Professor of health policy in the School of Population and Public Health. An expert in pharmaceutical policy, Dr. Morgan’s research helps governments balance three sometimes-competing goals: providing equitable access to necessary medicines, managing health care spending responsibly, and providing incentive for valued innovation. Dr. Morgan has published over 100 peer-reviewed research papers on pharmaceutical policies. He has advised governments in Canada and abroad and has produced work for the World Health Organization and the Organization for Economic Cooperation and Development.

Dr. Morgan earned degrees in economics from the University of Western Ontario, Queen’s University, and the University of British Columbia. He received post-doctoral training in health care policy at McMaster University and UBC.

Specialties: pharmaceutical policy, health care financing and expenditures, health policy analysis, health services research, equity analysis.

Dr. Morgan has received career awards from the Canadian Institutes of Health Research, the Michael Smith Foundation for Health Research, the Commonwealth Fund, McMaster University, and the University of British Columbia.

Dr Morgan has published over 150 articles, book chapters, and reports for governments. He also writes regular editorials for major newspapers and blog posts for websites such as and Huffington Post.

Peer-reviewed research articles publications in past 5 years


  1. Renwick, M.J., K. Smolina, E.J. Gladstone, D. Weymann, and S. Morgan. (2016) “Post-market policy considerations for biosimilar oncology drugs” Lancet – Oncology 17(1): e31–e38
  2. Gladstone, E., K. Smolina, S. Morgan, K. Fernandez, and T. Gomez (2015) “Identifying prescription opioid-related deaths in administrative mortality data in Ontario, Canada: a validation study” Canadian Medical Association Journal (CMAJ)
  3. Gladstone, E., K. Smolina, K. Rutherford, and S. Morgan (2015) “Geographic variations in prescription opioid purchases and deaths among women and men in British Columbia, Canada” Medical Care 53: 954–959
  4. Smolina, K., L. Ball, N. Khan, K. Humphries, and S. Morgan (2015) “Sex disparities in post-acute myocardial infarction pharmacologic treatment initiation and adherence: a problem for young women” Circulation: Cardiovascular Quality and Outcomes 8(6): 586-92
  5. Gladstone, E., K. Smolina, and S. Morgan (2015) “Trends and sex differences in prescription opioid deaths in British Columbia” BMJ Injury Prevention doi:10.1136/injuryprev-2015-041604
  6. Law, M., L. Cheng, J. Kratzer, S. Morgan, C. Marra, L. Lynd, and S. Majumdar. (2015) “The Impact of Allowing Pharmacists to Independently Renew Prescriptions: A Population-Based Study” Journal of the American Pharmacists Association e333-e339. doi:10.1331/JAPhA.2015.14262
  7. Smolina, K., G. Hanley, B. Mintzes, T. Oberlander, and S. Morgan (2015) “Trends and determinants of prescription drug use during pregnancy and postpartum in British Columbia, 2002-2011: a population-based cohort study” PLOS ONE DOI: 10.1371/journal.pone.0128312
  8. Smolina, K., D. Weymann, C. Ross, S. Morgan, and B. Carleton (2015) “Association between regulatory advisories and codeine prescribing to postpartum women” Journal of the American Medical Association (JAMA) 313(18):1861-1862
  9. Morgan, S., M. Law, J. Daw, L. Abraham, and D. Martin. (2015) “Estimated cost of universal public coverage of prescription drugs in Canada.” Canadian Medical Association Journal (CMAJ) 187(7):491-7. doi: 10.1503/cmaj.141564
  10. Smolina, K., and Morgan, S. (2014) “The drivers of overspending on prescription drugs in Quebec” Healthcare Policy 10(2): 19-26
  11. Daw, J., Morgan, S., Patricia Collins, and J Abelson (2014) “Framing incremental expansions to public health insurance systems: the case of Canadian pharmacare” Journal of Health Policy, Politics, and Law 39(2): 295-319
  12. Hasan, H., F. Howard, S. Morgan, D. Metzger, S. Gill, M. Johnson, A. Lo, and K. Goddard (2014) “Provincial Disparities of Growth Hormone Coverage for Young Adult Survivors of Paediatric Brain Tumours across Canada” Healthcare Policy 9(3): 80-96
  13. Morgan, S., P. Thomson, J. Daw, and M. Friesen (2013) “Canadian policy makers’ views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers” Health Policy 112(3): 248-254.
  14. Morgan, S., P. Thomson, J. Daw, and M. Friesen (2013) “Use of product listing agreements by provincial drug benefit plans” Healthcare Policy / Politiques de Santé 8(4):45-55.
  15. Puyat, Y., J. Daw, C. Cunningham, M. Law, S. Wong, D. Greyson, and S. Morgan.  (2013) “Racial and ethnic disparities in antipsychotic medication use: a systematic review and meta-analysis” Social Psychiatry and Psychiatric Epidemiology 48(12):1861-72
  16. Law, M., J. Daw, L Cheng, and S. Morgan. (2013) “Growth in private payments for health care by Canadian households” Health Policy 110(2): 141-146
  17. Morgan, S., J. Daw, and P. Thomson (2013) “International Best Practices For Negotiating ‘Reimbursement Contracts’ With Price Rebates From Pharmaceutical Companies” Health Affairs 32(4): 771-777.
  18. Daw, J., S. Morgan S., P. Thomson, and M. Law.  (2013) “Here today, gone tomorrow: the issue attention cycle and national print media coverage of prescription drug financing in Canada” Health Policy 110(1): 67-75
  19. Morgan, S., P. Thomson, J. Daw, and M. Friesen (2013) “Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces” BMC HSR 2013 Jan 31;13:34. doi: 10.1186/1472-6963-13-34
  20. So, L., Quan, H., and S. Morgan (2012) “Does concordance between survey responses and administrative records differ by ethnicity for prescription medication?” Journal of Population Therapeutics and Clinical Pharmacology 19(2):e248-58.
  21. Morgan, S. and J. Daw (2012) “Pharmacare in Canada: looking back, looking forward” Healthcare Policy / Politiques de Santé 8(1): 14-23
  22. Puyat, J., M. Law, S. Wong, J. Sutherland, and S. Morgan (2012) “Essential and potentially inappropriate antipsychotic use across income groups: an analysis of linked administrative data?” Canadian Journal of Psychiatry 57(8):488–495
  23. Law, M., L. Cheng, D. Heard, I. Dhalla, and S. Morgan. (2012) “The effect of cost on adherence to prescription medications in Canada” CMAJ 184(3): 297-302. **
  24. Daw, J., B. Mintzes, M. Law, G. Hanley, and S. Morgan (2012) “Prescription drug use in pregnancy: a retrospective population-based study in British Columbia, Canada (2001-2006). Clinical Therapeutics 34(1): 239-249
  25. Law, M., Y. Kawasumi, and S. Morgan. (2011) “Despite Law, Fewer Than One In Five Completed Studies Of Drugs And Biologics Are Reported On Time On” Health Affairs 30 (12) 2338-2345
  26. Daw, J., and S. Morgan (2012) “Stitching the gaps in the Canadian public drug coverage patchwork? A review of provincial pharmacare policy changes from 2000 to 2010” Health Policy 104(1): 19-26
  27. Greyson, D., C. Cunningham, and S. Morgan (2012) “Information seeking experiences of Canadian pharmaceutical policy makers” Health Information and Libraries Journal 29(1): 16–27, March 2012 doi: 10.1111/j.1471-1842.2011.00969.x
  28. Puyat, J., G. Hanley, C. Cunningham, M. Law, S. Wong, J. Sutherland, and S. Morgan (2011) “Ethnic disparities in antipsychotic drug use in British Columbia: a cross-sectional retrospective study of linked survey and administrative data” Psychiatric Services 62(9): 1026-1031
  29. Morgan, S. and C. Cunningham (2011) “Population aging and the determinants of health care expenditures: the case of hospital, medical, and pharmaceutical care in British Columbia, 1996 to 2006”  Healthcare Policy / Politiques de Santé 7(1): 68-79
  30. Law, M., A. Ystma, and S. Morgan. (2011) “The Short-term Impact of Ontario’s Generic Pricing Reforms” PLoS ONE 6(7): e23030
  31. Daw, J., G. Hanley, D. Greyson, and S. Morgan (2011) “Prescription drug use during pregnancy in developed countries: a systematic review” Pharmacoepidemiology and Drug Safety 20(9): 895-902. DOI: 10.1002/pds.2184
  32. Law, M., B. Mintzes, and S. Morgan. (2011) “Sources and popularity of online drug information: an analysis of top search engine results and web page views” Annals of Pharmacotherapy 45(3):350-6
  33. Hanley G., S. Morgan, and R. Reid. (2011) “Income-related inequity in initiating on evidence-based therapies among patients with acute myocardial infarction” Journal of General Internal Medicine DOI: 10.1007/s11606-011-1799-1
  34. Law, M. and S. Morgan. (2011) “Purchasing prescription drugs in Canada: hang together or hang separately” Healthcare Policy / Politiques de Santé 6(4): 22-26
  35. Morgan, S., G. Hanley, C. Cunningham, and H. Quan. (2011) “Ethnic differences in the use of prescription drugs in British Columbia: a cross-sectional analysis of linked survey and administrative data” Open Medicine 5(2)
  36. Cunningham, C., G. Hanley, and S. Morgan (2011) “Income inequities in End-of-life Health Care Spending in British Columbia, Canada: a pooled cross-sectional analysis” International Journal for Equity in Health 10:12 doi:10.1186/1475-9276-10-12
  37. Hanley G., S. Morgan, M. Barer, and R. Reid. (2011) “The redistributive effect of the move from age-based to income-based prescription drug coverage in British Columbia, Canada” Health Policy doi:10.1016/j.healthpol.2010.12.005
  38. Chafe, R, A. Culyer, M. Dobrow, P. Coyte, C. Sawka, S. O’Reilly, K. Laing, M. Trudeau, S. Smith, J. Hoch, S. Morgan, S. Peacock, R. Abbott, and T. Sullivan. (2011) “Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions” Healthcare Policy / Politiques de Santé 6(3): 28-36
  39. Law, M., A. Dijkstra, J. Douillard, and S. Morgan. (2011) “Geographic Accessibility of Community Pharmacies in Ontario” Healthcare Policy / Politiques de Santé 6(3): 36–46
  40. Morgan, S., P. Grootendorst, J. Lexchin, C. Cunningham, and D. Greyson. (2011) “The cost of drug development: a systematic review of published literature” Health Policy 100(1): 4-17 doi:10.1016/j.healthpol.2010.12.002
  41. Morgan, S., C. Cunningham, and G. Hanley. (2010) “Individual and Contextual Determinants of Regional Variation in Prescription Drug Use: An Analysis of Administrative Data from British Columbia” PLoS One 5(12): e15883 doi: 10.1371/journal.pone.0015883.
  42. Greyson, D., A. Becu, and S. Morgan (2010) “Sex, drugs and gender roles: Mapping the use of sex and gender based analysis in pharmaceutical policy research” International Journal for Equity in Health 9(2) doi:10.1186/1475-9276-9-26
  43. Greyson, D., S. Morgan, and C. Cunningham (2010) “Information-Seeking Experiences of Pharmaceutical Policy Makers” International Journal of Qualitative Methods 9(4): 409.
  44. Pomey, M.-P., S. Morgan, J. Church, P.-G. Forest, J. Lavis, T. McIntosh, N. Smith, J. Petrela, E. Martin, and S. Dobson (2010) “Do Provincial Drug Initiatives Create an Effective Policy Laboratory: The Evidence from Canada” Journal of Health Politics, Policy and Law 35(5): 705-742
  45. Law, M., S. Morgan, S. Majumdar, L. Lynd, and C. Marra. (2010) “Study protocol: Effects of prescription adaptation by pharmacists” BMC Health Services Research 10(1): 313 (doi:10.1186/1472-6963-10-313)
  46. Morgan, S., and C. Cunningham. (2010) “Listening for Prescriptions: A National Consultation on Pharmaceutical Policy Issues” Healthcare Policy / Politiques de Santé 6(2): 48-66
  47. Morgan, S., K. Orr, and C. Mah. (2010) “Graduate attributes for master’s programs in health services and policy research: results of a national consultation.” Healthcare Policy / Politiques de Santé 6(1): 64-86
  48. Hanley G., S. Morgan, and R. Reid. (2010) “Explaining prescription drug use and expenditures using the adjusted clinical groups (ACG) case-mix system in the population of British Columbia, Canada.” Medical Care 48(5): 402-408 doi: 10.1097/MLR.0b013e3181ca3d5d
  49. Cunningham, C., G. Hanley, and S. Morgan. (2010) “Patterns in the use of benzodiazepines in British Columbia” Health Policy 97(2-3):122-129 doi:10.1016/j.healthpol.2010.03.008
  50. Leong V., S. Morgan, S. Wong, G. Hanley, and C. Black. (2010) “Registration for public drug benefits across areas of differing ethnic composition in British Columbia, Canada.” BMC HSR 10:171doi:10.1186/1472-6963-10-171
  51. Morgan, S., and K. Boothe. (2010) “Prescription drug subsidies in Australia and New Zealand” (peer-reviewed editorial) Australian Prescriber 33(1): 2-4.
SPPH 542 Canadian Health Policy
SPHA 510 Canadian Health Policy and the Health Care System

Graduate Students:

Suzie Maginley

An expert in pharmaceutical policy, Dr. Morgan’s research helps governments balance three sometimes-competing goals: providing equitable access to necessary medicines, managing health care spending responsibly, and providing incentive for valued innovation.